Clinical trials: Bile Duct Neoplasms Malignant
Cholangiocarcinoma, Klatskin Tumor
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting.
- Conditions
- Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
- Trial name
- ACTICCA-2 (NCT06175845)
- Testing
- Intraductal biliary radiofrequency ablation
- Where
- 9 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Bile Duct Adenocarcinoma, Bile Duct Carcinoma
Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories
This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures.
- Trial name
- NCT07120295
- Testing
- Dragonfly™ Digital Pancreaticobiliary System
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Colorado, Denver
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Bladder Carcinoma, Gastric Carcinoma
Patient-Derived Xenografts to Reduce Cancer Health Disparities
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities.
- Conditions
- Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma
- Trial name
- NCT04410302
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of California, Davis
Pancreatic Cancer Non-resectable, Bile Duct Cancer
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
The goal of this randomized controlled trial is to compare uncovered, partially covered, and fully covered self-expandable metal stents (SEMS) in the palliative treatment of distal malignant biliary obstruction in a Swedish…
- Conditions
- Pancreatic Cancer Non-resectable, Bile Duct Cancer, Papillary Carcinoma, Duodenal Cancer
- Trial name
- NCT06453590
- Testing
- Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.
- Where
- 12 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- Region Stockholm
Biliary Tract Carcinoma, Cholangiocarcinoma
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC).
- Conditions
- Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT06048133
- Testing
- Gemcitabine, Cisplatin, Zimberelimab
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Nataliya Uboha
Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
This phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating…
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma
- Trial name
- NCT07765433
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 336 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Surgery, Stomach Cancer
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery >3 hours, and (3) curative-intent surgical resection…
- Conditions
- Surgery, Stomach Cancer, Pancreas Cancer, Bile Duct Cancer
- Trial name
- NCT07653594
- Testing
- Music-assisted relaxation and imagery (MARI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
This phase I trial studies the side effects of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel in combination with gemcitabine and cisplatin in treating patients with biliary tract cancer that has…
- Conditions
- Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
- Trial name
- NCT05285358
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
The BILLIONSTARS study is a prospective, single arm observational study inviting patients diagnosed with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) who are to be recommended locoregional intervention by surgery…
- Trial name
- BILLIONSTARS (NCT06877637)
- Where
- 3 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the…
- Conditions
- Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04491942
- Testing
- Cisplatin, Elimusertib, Gemcitabine Hydrochloride
- Where
- 8 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Bile Duct Carcinoma, Cholangiocarcinoma
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
This study is a prospective, multicenter, open-label, umbrella phase II clinical trial. Based on different multigene expression profiling subtypes and potential molecular characteristics of various pathways, 8 treatment arms and…
- Trial name
- NCT07729917
- Testing
- FGFR Inhibitor, IDH1 mutation inhibitor, KRAS mutation inhibitor
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang University
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the…
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704216
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Bile Duct Cancer, Gall Bladder Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous…
- Conditions
- Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors
- Trial name
- NCT05000294
- Testing
- Atezolizumab, Tivozanib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Florida
Peritoneal Carcinomatosis, Peritoneal Metastases
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase…
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer
- Trial name
- PIPAC-NAL-IRI (NCT05277766)
- Testing
- PIPAC with Nal-IRI
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Cholangiocarcinoma
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure…
- Trial name
- NCT05874414
- Testing
- GNS561 + Trametinib
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Genfit
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
This clinical trial studies positron emission tomography (PET)-computed tomography (CT) in determining the radiation dose delivered with radioactive spheres to patients with liver metastasis or primary liver or biliary cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02088775
- Testing
- PET scan, CT Scan, hepatic artery embolization
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients…
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04251715
- Testing
- Dexamethasone, Floxuridine, Implanted Medical Device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute